Duncker Streett & Co’s Bristol-Myers Squibb BMY Stock Holding History

Duncker Streett & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54M	Buy	41,948 +400	+1%	+$23.3K	0.48%	49
2025 Q4	$2.24M	Hold	41,548	–	–	0.4%	63
2025 Q3	$1.87M	Sell	41,548 -1,790	-4%	-$83.6K	0.33%	69
2025 Q2	$2.01M	Sell	43,338 -1,743	-4%	-$85.6K	0.37%	69
2025 Q1	$2.75M	Sell	45,081 -20	-0%	-$1.17K	0.54%	46
2024 Q4	$2.55M	Sell	45,101 -960	-2%	-$53.6K	0.47%	56
2024 Q3	$2.38M	Sell	46,061 -2,207	-5%	-$104K	0.43%	67
2024 Q2	$2M	Sell	48,268 -3,895	-7%	-$174K	0.39%	68
2024 Q1	$2.83M	Sell	52,163 -3,839	-7%	-$196K	0.56%	54
2023 Q4	$2.87M	Sell	56,002 -1,999	-3%	-$105K	0.61%	54
2023 Q3	$3.37M	Sell	58,001 -718	-1%	-$44K	0.78%	38
2023 Q2	$3.76M	Sell	58,719 -2,165	-4%	-$145K	0.84%	35
2023 Q1	$4.22M	Sell	60,884 -1,141	-2%	-$80.5K	1.01%	28
2022 Q4	$4.46M	Buy	62,025 +394	+0.6%	+$29.7K	1.08%	23
2022 Q3	$4.38M	Sell	61,631 -1,710	-3%	-$124K	1.14%	19
2022 Q2	$4.88M	Sell	63,341 -325	-0.5%	-$24.8K	1.17%	17
2022 Q1	$4.65M	Buy	63,666 +17,667	+38%	+$1.19M	0.92%	27
2021 Q4	$2.87M	Buy	45,999 +5,490	+14%	+$322K	0.49%	62
2021 Q3	$2.4M	Sell	40,509 -84	-0.2%	-$5.53K	0.45%	74
2021 Q2	$2.71M	Sell	40,593 -14,309	-26%	-$933K	0.5%	67
2021 Q1	$3.47M	Sell	54,902 -4,272	-7%	-$266K	0.66%	47
2020 Q4	$3.67M	Sell	59,174 -1,752	-3%	-$108K	0.71%	46
2020 Q3	$3.67M	Sell	60,926 -1,540	-2%	-$92.7K	0.8%	38
2020 Q2	$3.67M	Sell	62,466 -1,141	-2%	-$68.2K	0.87%	32
2020 Q1	$3.55M	Buy	63,607 +531	+0.8%	+$32.5K	0.95%	27
2019 Q4	$4.05M	Buy	63,076 +5,707	+10%	+$327K	0.85%	35
2019 Q3	$2.91M	Buy	57,369 +157	+0.3%	+$7.38K	0.68%	49
2019 Q2	$2.6M	Sell	57,212 -554	-1%	-$25.8K	0.58%	56
2019 Q1	$2.76M	Buy	57,766 +82	+0.1%	+$4.08K	0.64%	48
2018 Q4	$3M	Sell	57,684 -3,261	-5%	-$175K	0.8%	33
2018 Q3	$3.78M	Buy	60,945 +14	+0%	+$831	0.86%	24
2018 Q2	$3.37M	Sell	60,931 -641	-1%	-$34.6K	0.84%	26
2018 Q1	$3.9M	Sell	61,572 -103	-0.2%	-$6.63K	0.99%	16
2017 Q4	$3.78M	Sell	61,675 -742	-1%	-$46.4K	0.97%	20
2017 Q3	$3.98M	Sell	62,417 -529	-0.8%	-$30.9K	1.2%	12
2017 Q2	$3.51M	Buy	62,946 +2,177	+4%	+$118K	1.09%	15
2017 Q1	$3.31M	Buy	60,769 +4,972	+9%	+$273K	1.04%	20
2016 Q4	$3.26M	Buy	55,797 +5,286	+10%	+$289K	1.08%	17
2016 Q3	$2.72M	Buy	50,511 +3,070	+6%	+$197K	0.94%	27
2016 Q2	$3.49M	Buy	47,441 +657	+1%	+$46.4K	1.24%	13
2016 Q1	$2.99M	Buy	46,784 +2,353	+5%	+$148K	1.11%	20
2015 Q4	$3.06M	Buy	44,431 +3	+0%	+$198	1.15%	17
2015 Q3	$2.63M	Sell	44,428 -1,297	-3%	-$82.3K	1.02%	23
2015 Q2	$3.04M	Buy	45,725 +3	+0%	+$198	1.06%	18
2015 Q1	$2.95M	Sell	45,722 -872	-2%	-$54.6K	0.97%	26
2014 Q4	$2.75M	Buy	46,594 +3	+0%	+$169	0.9%	26
2014 Q3	$2.38M	Buy	46,591 +3	+0%	+$150	0.81%	30
2014 Q2	$2.26M	Buy	46,588 +186	+0.4%	+$9.17K	0.73%	34
2014 Q1	$2.41M	Sell	46,402 -1,340	-3%	-$71.3K	0.85%	26
2013 Q4	$2.54M	Sell	47,742 -141	-0.3%	-$7.18K	0.91%	22
2013 Q3	$2.22M	Buy	47,883 +11	+0%	+$483	0.9%	22
2013 Q2	$2.14M	Buy	+47,872	New	+$2.08M	0.82%	33

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Duncker Streett & Co's BMY Position: Q1 2026 in Review

Duncker Streett & Co increased its Bristol-Myers Squibb (BMY) stake by 0.96% in Q1 2026, buying an estimated $23.3K and bringing the position to 41,948 shares worth $2.54M. The position accounts for 0.48% of the portfolio, ranked #49.

Duncker Streett & Co first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.88M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Duncker Streett & Co held 41,948 shares of Bristol-Myers Squibb worth $2.54M as of Q1 2026.
Duncker Streett & Co bought 400 Bristol-Myers Squibb shares in Q1 2026, an estimated $23.3K.
Bristol-Myers Squibb made up 0.48% of Duncker Streett & Co's portfolio in Q1 2026, its #49 holding.
Duncker Streett & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
Duncker Streett & Co's Bristol-Myers Squibb position peaked at $4.88M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Duncker Streett & Co's 13F filing for Q1 2026, filed 29 Apr 2026.